NOTTINGHAM, England, May 18, 2010 /PRNewswire/ -- Compandia is pleased to announce the appointment of its new non exec chairman Dr Dave Tapolczay. Dave is CEO of Medical Research Council Technology, the commercialisation company for the MRC. Compandia CEO, Andy Sutton announced, We are thrilled that Dave has joined Compandia and will bring significant experience from his years at GSK, Millenium, Pharmorphix and AZ. Dave will add a strategic view from both the large International Corporate and Start Up perspectives and bring a wealth of knowledge regarding current trends affecting the Pharma and Biotech Sectors which will assist Compandia in positioning its services for optimal delivery.

Compandia is a biomarker discovery and bioinformatics spin out from Nottingham Trent University. Compandia uses advanced bioinformatics tools to derive biomarker panels from complex biological data being generated in the Pharmaceutical, Biotech and Biomedical sectors. Compandia's advantage is the ability to find small biomarker panels from data that would otherwise be impossible to decipher this enables disease states to be accurately diagnosed from a small number of analytes.

Compandia in addition offers proteomic services coupled to its Biomarker Distiller for the discovery of proteomic biomarker panels. Compandia has successfully delivered panels of 3-6 proteins: for the stratification of patients into responders and non responder prior to prostate cancer therapy; for staging of melanoma patients based on a serum signature and identification of mild cognitive impairment [MCI] patients as a clearly defined cohort tending towards Alzheimer's disease. Biomarker Distiller has also been applied to gene array, micro RNA array and Next Gen sequencing datasets comfortably delivering biomarker panels of 3-8 genes defining melanoma, breast prostate and lung cancer patient cohorts suitable for therapy.

Compandia also announced the launch of a new bioinformatics capability, its Pathways Distiller bioinformatics tool that creates maps of interacting gene pathways which define patient populations such as drug responders from non responders. This unique tool allows researchers to identify key nodes where interactions take place that may represent new drug targets or offer insight into mechanisms of therapy failure. Compandia CEO, Andy Sutton explained, Pathways Distiller gives us completely new insight into biological states defined by detailed pathway maps which will prove beneficial to companies planning combination therapies.

If you require further information please contact Dr Andy Sutton CEO on +44(0)7764-580468 or e-mail andy.suttton@compandia.co.uk, website http://www.compandia.co.uk

SOURCE: Compandia Ltd

CONTACT: If you require further information please contact Dr Andy SuttonCEO on +44(0)7764-580468 or e-mail andy.suttton@compandia.co.uk